Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Altasciences has named Gaetano Morelli the company’s chief medical officer. Morelli was most recently a medical consultant and principal investigator of clinical trials at Altasciences.
Amplyx Pharmaceuticals has appointed Chris LeMasters to the role of chief operating officer and Carlos Sattler to the position of senior vice president of clinical development. LeMasters was most recently the chief business officer at Mirati Therapeutics; Sattler comes to Amplyx from Halozyme Therapeutics, where he served as vice president of global medical and scientific affairs.
Donald Lung has been named chief financial officer of Antengene. Lung was most recently a senior analyst at Hong Kong-based Myriad Asset Management.
Justin Renz, former president and chief financial officer of Correvio Pharma, has been appointed chief financial officer of Ardelyx.
Chris Cabell, the senior vice president and chief medical officer at Arena Pharmaceuticals, has assumed the additional roles of executive vice president and head of research and development.
Arix Bioscience has appointed Christian Schetter, the company’s entrepreneur in residence, to the role of managing director. Schetter was CEO of Rigontec prior to joining Arix.
Kyle Landskroner has been appointed head of preclinical drug development at Azafaros. Previously, Landskroner was director of global integration and separation office at Novartis. Ruben Giorgino, former global head of clinical research and development at the Helsinn Group, was named head of clinical research and development at Azafaros. Additionally, Louise Kooij was named head of finance and operations. Kooij was most recently head of rare diseases for central and eastern Europe at Sanofi-Genzyme.
Jeffrey Humphrey has been hired to the position of chief medical officer at Constellation Pharmaceuticals. He will assume this position following his departure from Kyowa Kirin, where he served as the company’s chief development officer.
DalCor Pharmaceuticals has appointed Diane Sullivan to the role of chief commercial officer. Prior to joining DalCor, Sullivan was chief commercial officer at The Medicines Company.
Jason O’Neill has been named CEO of biopharmaceutical company Dendreon. Most recently, O’Neill was president at Cardinal Academy.
Franck Brinkhaus, chief financial officer of EpicentRx, has been named president of the company. Prior to joining EpicentRx, Brinkhaus was managing director at Woodside Capital Partners.
Immatics Biotechnologies has appointed Cedrik Britten to the role of chief medical officer. Britten joins the company from GlaxoSmithKline, where he served as vice president and head of the oncology cell therapy research unit.
Pierre-Alain Ruffieux has been named CEO of Lonza Group, a role he will assume on Nov. 1. Currently, Ruffieux is head of global pharma technical operations at Roche.
Yael Hayon has been hired to the role of vice president of research and development at Protalix BioTherapeutics. Hayon was previously the vice president of clinical affairs of Syqe Medical, Tel-Aviv.
Michael Donaldson has been named chief financial officer of Summit Therapeutics. Donaldson was most recently vice president of finance and corporate controller at Goldfinch Bio.